Free Trial

Chemed (NYSE:CHE) Reaches New 12-Month Low - Here's What Happened

Chemed logo with Medical background

Chemed Corporation (NYSE:CHE - Get Free Report)'s stock price reached a new 52-week low on Monday . The stock traded as low as $449.01 and last traded at $450.09, with a volume of 91785 shares changing hands. The stock had previously closed at $451.30.

Analysts Set New Price Targets

Several analysts recently weighed in on CHE shares. Royal Bank Of Canada restated an "outperform" rating and set a $640.00 price target (down previously from $674.00) on shares of Chemed in a report on Monday, June 30th. Bank of America decreased their price target on Chemed from $708.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 30th. Finally, Wall Street Zen lowered Chemed from a "buy" rating to a "hold" rating in a report on Saturday, July 5th.

Check Out Our Latest Stock Analysis on Chemed

Chemed Trading Down 0.5%

The company has a 50-day simple moving average of $524.68 and a 200 day simple moving average of $556.39. The company has a market cap of $6.78 billion, a P/E ratio of 22.58, a P/E/G ratio of 2.24 and a beta of 0.50.

Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $5.63 EPS for the quarter, beating the consensus estimate of $5.59 by $0.04. The company had revenue of $646.94 million for the quarter, compared to the consensus estimate of $641.78 million. Chemed had a return on equity of 27.58% and a net margin of 12.40%. Chemed's quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.20 EPS. On average, equities analysts forecast that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Thursday, May 29th were given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend was Thursday, May 29th. Chemed's dividend payout ratio (DPR) is presently 9.74%.

Insider Buying and Selling at Chemed

In other Chemed news, EVP Spencer S. Lee sold 1,500 shares of the company's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $577.99, for a total value of $866,985.00. Following the transaction, the executive vice president owned 14,627 shares of the company's stock, valued at $8,454,259.73. This represents a 9.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kevin J. Mcnamara sold 1,500 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $576.45, for a total value of $864,675.00. Following the completion of the transaction, the chief executive officer directly owned 101,197 shares in the company, valued at $58,335,010.65. This trade represents a 1.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,500 shares of company stock worth $2,598,450 in the last ninety days. 3.29% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Chemed

A number of hedge funds and other institutional investors have recently made changes to their positions in CHE. Alpine Bank Wealth Management bought a new position in shares of Chemed during the 1st quarter worth $29,000. HM Payson & Co. bought a new position in shares of Chemed during the 1st quarter worth $30,000. SVB Wealth LLC bought a new position in shares of Chemed during the 1st quarter worth $30,000. Whipplewood Advisors LLC grew its position in shares of Chemed by 54.5% during the 1st quarter. Whipplewood Advisors LLC now owns 51 shares of the company's stock worth $31,000 after buying an additional 18 shares in the last quarter. Finally, WPG Advisers LLC bought a new position in shares of Chemed during the 1st quarter worth $32,000. Institutional investors own 95.85% of the company's stock.

Chemed Company Profile

(Get Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Recommended Stories

Should You Invest $1,000 in Chemed Right Now?

Before you consider Chemed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.

While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines